DTIL - Precision BioSciences Inc

Recent News

Precision BioSciences ( DTIL ) Reports Q2 Loss, Lags Revenue Estimates

Zacks Commentary • 1 month, 1 week ago • score: 0.10

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -2,266.67% and -99.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Neutral

Precision BioSciences ( DTIL ) Reports Q1 Loss, Lags Revenue Estimates

Zacks Commentary • 4 months ago • score: 0.07

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -413.95% and 99.71%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Neutral

DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up

Zacks Commentary • 4 months, 4 weeks ago • score: 0.12

Precision BioSciences stock soars 24% as the FDA grants the Fast Track designation to its PBGENE-HBV gene therapy for potentially curing chronic hepatitis B.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company is headquartered in Durham, North Carolina.

52W High

$10.71

52W Low

$3.61

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.61

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

11.03

EV/EBITDA (<8 favorable)

-0.27

EV/Revenue (<3 favorable)

21.38

P/S (TTM) (<3 favorable)

47.39

P/B (<3 favorable)

1.76

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

11.28%

Institutions (25–75% balanced)

44.24%

Shares Outstanding

11,787,000

Float

10,554,900

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

1,261,000

Gross Profit (TTM)

1,261,000

EPS (TTM)

-10.15

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-1215.39%

ROE (TTM) (>15% strong)

-1.44%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-1.00

Momentum

Value

N/A

Trend

—

Signal Cross

No cross

As of

—